Scholar Rock (SRRK), a late-stage biopharmaceutical company, will present additional data from its phase III SAPPHIRE clinical trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 16-19 in Dallas, Texas.
SAPPHIRE is a phase III trial assessing the efficacy and safety of the company's lead drug candidate, Apitegromab, in children aged 2 to 12 with spinal muscular atrophy who are being treated with survival motor neuron (SMN)-targeted therapies, such as Biogen/Ionis' Spinraza or Roche's Evrysdi.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.